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Unbiased discovery approaches have the potential to uncover neurobiological insights into CNS disease
and lead to the development of therapies. Here, we review lessons learned from imaging-based screening
approaches and recent advances in these areas, including powerful new computational tools to synthesize
complex data into more useful knowledge that can reliably guide future research and development.Introduction
As integrative biology (Blow, 2009) reshapes paradigms in cell
biology, it is increasingly clear that many of the phenotypes
we seek to measure in isolation are highly connected to each
other (Collinet et al., 2010). In fact, cells and their phenotypes
exhibit many features that qualify them as complex systems:
phenotypes are often emergent properties of dynamic signaling
pathways with nested feedback loops, non-linear signaling
relationships, and the capacity to undergo adaptive changes.
Complex systems are challenging to understand using stan-
dard hypothesis-driven experimental approaches that aim to
manipulate one variable at a time. Holding every other variable
constant in complex biological systems may be impossible or
require artificial measures that confound results. Certain biases
are unavoidable, and the investigator’s knowledge and concep-
tual framework limit the pace of discovery. Indeed, the instincts
scientists have developed by studying well-defined simple
biological systems may mislead them as much as guide them
when applied to complex systems. Breakthroughs and paradigm
shifts are infrequent and often result from serendipity rather than
intention because the hypotheses that drive experimental design
evolve slowly from past results.
Discovery or ‘‘hypothesis-free’’ approaches are an important
alternative.Whereas hypothesis-driven research is linear, discov-
ery approaches are massively parallel. Since the ‘‘system’’—the
cell in this case—tells the investigator which perturbation is
relevant, discoveries can be unexpected and less biased than
findings from hypothesis-driven approaches. One of the most
common applications is imaging-based phenotypic screens in
cells. Cell-based screens have provided novel biological insights
into the genes that control cell morphology (Jones et al., 2009),
chromosome segregation and structure (Neumann et al., 2006;
Walter et al., 2010), cell division,migration and survival (Neumann
et al., 2010), susceptibility to infection (Cronin et al., 2009),
and regulators of the protein clearance pathway autophagy
(Orvedahl et al., 2011). In neuroscience, cell-based screens
(Al-Ali et al., 2013) have been used effectively to investigate
regenerative approaches to multiple sclerosis (Deshmukh et al.,
2013) and synaptogenesis (Sharma et al., 2013; Shi et al., 2011).160 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.Commensurate analysis tools must be applied that treat cells
as defined but complex systems (Freddolino and Tavazoie,
2012; Karr et al., 2012). Fortunately, large-scale computational
facilities are changing the nature of data analysis. They have
increased the ability to access and search data, improved visu-
alization techniques and technologies, enabled the application
of powerful statistical techniques to large complex data sets,
and made it possible to apply previously computationally unten-
able machine learning (ML) techniques to build predictive
models of complex biological systems.
In the sections that follow, we will review some of the lessons
learned from past efforts with cell-based screens, some impor-
tant considerations for those pursuing these approaches now
and for the future, including the challenges and opportunities
created by the massive amounts of data that these screens
can generate. Our focus is imaging and cell-based screens
applied to neurobiology, though the concepts and approaches
described here are widely relevant. We will look at the methods
for acquiring images, how images are analyzed, the value of
cloud computing and ML, and the implications of all of this for
the future of biology and medicine.
Model Systems
There are several key components of any screen, and the first is
the cells to be examined (Figure 1). This choice is critical and
should be driven by the biological question rather than expedi-
ence. The basic choice is between immortalized cells and
primary cells, and more recently, cells derived from induced
pluripotent stem cells (iPSCs).
Ultimately, a compromise between feasibility and biological
relevance may be needed to conduct a screen. The trade-
offs—what can and can’t be learned from the in vitro system
and the endpoints examined—need to be understood clearly
before starting. For the purposes of this discussion, biological
relevance is the extent to which lessons from simple systems
that are feasible to use for screening hold true for the more com-
plex systems that they are meant to model. In this regard, vali-
dating models for use as screening platforms can be complex.
If the screen is focused on an aspect of biology observed in vivo,
• cell type, na e vs heterologous system
• species and ssue relevance
• disease relevant phenotypic endpoint
• good signal to noise ra o
• reproducibility
• automa on
• deﬁned phenotypic endpoints followed
• selec on of gene-level hits based on sta s cal 
tests
• rule out oﬀ-target eﬀects
• test in other cells
• selec on against undesirable phenotypes
• assess feasibility for SM or protein therapeu c
• assess on-target liability for toxicity
• expression analysis (diseased and normal)
• availability of models and tools
Figure 1. Generic Flow Scheme for Cell-Based High-Throughput
Screening
The basic stages of target discovery and selection are outlined.
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be based on the ability of the in vitromodel to replicate the critical
in vivo biology. For screens focused on discovering treatments
of a disease for which no effective therapies currently exist,
the options for true validation are limited. Investigators must
generally select a model based on a degree of face validity
until an effective therapy is found, which can then be used to
help validate and invalidate models. To be clear, no in vitro
system will display the complexity of an intact organism, and
not all biological insights will translate from in vitro to in vivo
model systems or ultimately to human patients.
New Options with iPSCs
The Nobel Prize-winning discovery of cellular reprogramming by
Takahashi and Yamanaka (2006), which led to the production
of human iPSCs, offers new possibilities for disease models
(Takahashi et al., 2007; Yu et al., 2007). Primary cells can be
collected from people and reprogrammed into a stem or precur-
sor cell that can be expanded and passaged (Churko et al., 2013;
Hayes and Zavazava, 2013; Warren et al., 2010). In turn, iPSCs
can be differentiated into cell types relevant to the disease,
including subtypes of neurons and glia.
Protocols to make different brain cell types are being rapidly
developed and improved. Many protocols involve the delivery
of critical instructive factors to cells in culture at specific times
and in a particular order to recapitulate key steps in development
(Kim et al., 2014). For example, efficient protocols have been
developed to make neural crest by dual-SMAD inhibition/WNT
activation (Chambers et al., 2013). Protocols have been reported
for making many brain cell types from stem cells, including
dopaminergic neurons (Studer, 2012; Sun et al., 2013; Sundberg
et al., 2013), motor neurons (Bilican et al., 2012; Boulting et al.,
2011; Di Giorgio et al., 2007), forebrain-like neurons (HD iPSCConsortium, 2012), striatal neurons (Aubry et al., 2008), cortical
interneurons (Maroof et al., 2013), retinal cells (Jin and Takaha-
shi, 2012), oligodendrocytes (Czepiel et al., 2011; Ogawa et al.,
2011; Wang et al., 2013; Yang et al., 2013), and astrocytes
(Emdad et al., 2012; Serio et al., 2013). Neurons and neural pro-
genitors can be produced directly from other types of somatic
cells without having to first make those cells pluripotent
(Ambasudhan et al., 2011; Kim et al., 2011; Vierbuchen et al.,
2010).
The application of iPSCs to studyingdiseasehasgenerated the
most excitement (Eglen and Reisine, 2011). For the first time, a
skin or blood cell from a patient with a neurological or psychiatric
disease can be reprogrammed to become a cell type of the ner-
vous system, thereby creating a genetically faithful humanmodel
of disease (Churko et al., 2013; Hayes and Zavazava, 2013;Wray
et al., 2012). Already, several models have been developed that
exhibit disease-relevant phenotypes (Table 1) for Huntington’s
disease (HD) (HD iPSC Consortium, 2012; Zhang et al., 2010),
amyotrophic lateral sclerosis (ALS) (Barmada et al., 2014; Bilican
et al., 2012; Burkhardt et al., 2013; Donnelly et al., 2013; Egawa
et al., 2012; Sareen et al., 2013; Serio et al., 2013), spinal
muscular atrophy (Ebert et al., 2009), Parkinson’s disease
(Cooper et al., 2012; Skibinski et al., 2014), schizophrenia (Bren-
nand et al., 2011), and Alzheimer’s disease (AD) (Israel et al.,
2012). In principle, genetic and SM screens can be conducted
in what might be the most physiologically relevant cell-based
model of neurological disease ever developed.
iPSCs might also help to solve one of the most vexing prob-
lems in drug development. Non-human models of neurological
disease have a poor track record for predicting results of putative
therapies in clinical trials (McGonigle, 2014; McGonigle and
Ruggeri, 2014), including HD (Crook and Housman, 2011), ALS
(Perrin, 2014), and AD (Mullane and Williams, 2013). Nearly all
the compounds that were tested in human clinical trials and
failed to show efficacy were supported by data showing that
the drugs were effective in mice. There were two exceptions:
tetrabenazine, a symptomatic therapy for HD, showed efficacy
in mice, and riluzole had modest effects in a mouse model of
ALS and extended the lives of ALS patients by a few months
on average. Some discrepancy can be blamed on the design
and execution of preclinical efficacy trials in mice (Perrin,
2014). But worrisome data suggest that more fundamental bio-
logical differences betweenmice and humansmay be important.
Humans and mice diverged in evolution over 65 million years
ago, and many publications show that results from mice fail
to reliably predict results from humans in drug absorption,
distribution, metabolism, elimination, toxicity, bioavailability,
carcinogenicity, teratogenicity, and efficacy, as well as disease
pathophysiology. Known differences in pharmacodynamics
(Richert et al., 2008; Xie et al., 2000) and toxicology (Carlson
et al., 2009; Singh and Gupta, 1985) between humans and
non-human models could affect drug safety. Differences exist
in physiological responses and drug effects in human cells
(e.g., neurons), compared to murine or other non-human coun-
terparts (Berger et al., 2006; Castan et al., 1994; Curtis et al.,
1997; Derian et al., 1995; Guo et al., 1989; Keshavaprasad
et al., 2005; Kopin et al., 1997; Liang et al., 2010; Mattson
et al., 1991; Okazaki et al., 1995; Penhoat et al., 1996; RasakhamNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 161
Table 1. Examples of Phenotypes Detected in Patient-Derived iPSCs
Disease Phenotype (s) Reference
Huntington’s disease Transcription dysregulation HD iPSC Consortium, 2012; Zhang et al., 2010
Cell-adhesion defects
Bioenergetic defects
Altered signal transduction pathway activation
Calcium dyshomeostasis
Survival and neurite deficits
Increased susceptibility to stressors
Amyotrophic lateral sclerosis Abnormal RNA foci formation Barmada et al., 2014; Bilican et al., 2012; Burkhardt et al.,
2013; Donnelly et al., 2013; Egawa et al., 2012; Sareen
et al., 2013; Serio et al., 2013; Wen et al., 2014a
Gene expression dysregulation
RNA binding protein sequestration
Abnormal protein aggregation
Altered electrical excitability
Survival deficits
Increased susceptibility to stressors
Spinal muscular atrophy Disease-relevant changes in SMN transcripts Ebert et al., 2009
Parkinson’s disease Mitochondrial dysfunction Cooper et al., 2012; Sanders et al., 2014; Skibinski
et al., 2014
Increased susceptibility to stressors
Survival deficits
Schizophrenia Reduced synaptic connectivity Brennand et al., 2011; Wen et al., 2014b
Decreased neurites
Altered synaptic protein levels
Synaptic vesicle release deficits
Gene expression dysregulation
Alzheimer’s disease Abnormal amyloid b, phosphorylated tau production Choi et al., 2014; Israel et al., 2012
Abnormal amyloid b plaque and neurofibrillary
tangle formation
Abnormal endosome accumulation
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to neuropeptides, hormones, and drugs, including anesthetics,
antiarrhythmics, and ligands for G protein-coupled and nuclear
receptors (Castan et al., 1994; Derian et al., 1995; Guo et al.,
1989; Keshavaprasad et al., 2005; Kopin et al., 1997; Liang
et al., 2010; Okazaki et al., 1995; Penhoat et al., 1996; Rasakham
and Liu-Chen, 2011). For the neurokinin NK1 (Pradier et al., 1995)
and the brain cholecystokinin CCK-B (Kopin et al., 1997) recep-
tors, two key drug targets, differences in just one or two amino
acids in the orthologous receptors resulted in major differences
in the efficacy of ligands for human and murine cells. Thus, an
advantage of iPSCs is that both on-target and off-target pharma-
cology of compounds can be assessed in the context of a fully
human system.
That a number of disease-relevant phenotypes have been
observed after only weeks or months in culture may be surpris-
ing: the symptoms of many of these diseases are not normally
evident for decades. However, the symptoms might be
misleading. Redundancy and copingmechanisms in the nervous
system are extensive and may obscure deficits until substantial
cell loss has occurred and coping mechanisms have been ex-162 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.hausted. Indeed, abnormalities at the cellular level may begin
much earlier, particularly in the case of genetic causes of these
diseases, and may be robustly detected with new and more
sensitive instrumentation described below (Clarke et al., 2000;
Finkbeiner, 2012). Also, the in vitro environmentmay be less sup-
portive than that in vivo, which may help to uncover differences
in the vulnerability of cells differentiated from patient-derived
iPSCs and controls.
Yet iPSCs are no universal panacea. More needs to be under-
stood about environmental causes of sporadic disease. If envi-
ronmental influences are mediated by epigenetic mechanisms
and those marks are erased during reprogramming, the utility
of the cells for modeling may be limited until it becomes possible
to reintroduce those epigenetic marks in the laboratory. Even
for genetic causes of disease, working with iPSCs has its own
set of challenges. iPSCs reprogrammed from the same parent
fibroblast exhibit variability. Some of this variability likely reflects
somatic mosaicism in the human tissue sample from which
the iPSCs are derived and the clonal nature of iPSC generation
(Abyzov et al., 2012). Variability due to random integration of
reprogramming factors should be less of an issue with newer
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et al., 2009). Though it is possible to differentiate iPSCs into
different nervous system cell types, the protocols vary signifi-
cantly in their efficiency, and some cell types remain difficult
or nearly impossible to make. The differentiation protocols
require weeks to months to execute, and the time and cost
are considerable.
Still, the investment in this field and its trajectory are aston-
ishing. We expect essentially every aspect of the utility of these
cells to continue to improve rapidly. The ambitious vision of
creating platforms of iPSCs with the requisite genetic diversity
to represent significant human populations to enable patient
stratification and ‘‘clinical trials in a dish’’ and, eventually,
personalized medicine approaches seems fanciful, but it is diffi-
cult at this time to see insurmountable obstacles to that goal.
Cell-Based Genetic Screens
Cell-based screens for genetic modifiers have the potential to
uncover therapeutic targets that can be moved forward to clin-
ical applications, even before the underlying mechanisms are
fully understood (Figure 1). This is critical because complex
diseases might otherwise require decades of hypothesis-driven
research to produce a sufficient biological understanding to
develop a rational intervention. The main cell-based approaches
to identify modifiers of biological or pathophysiological pro-
cesses involve the use of RNAi, cDNA expression, clustered
regularly interspaced short palindromic repeats (CRISPR)/
Cas9-mediated gene down or upregulation, or chemigenomics.
Chemigenomics is an approach that involves the use of libraries
of molecules whose specificity for their target is so well estab-
lished that it is straightforward to relate a hit from a screen to
the biological pathway that mediates the effects.
RNAi screens have been widely used in models of diseases
with features that can be assayed in vitro using surrogate end-
points. Surrogate endpoints are phenotypes that the investigator
believes are directly related to a pathway or pathogenic process
relevant to the disease that the system is designed to model
(the reader is referred to several reviews: Falschlehner et al.,
2010; Kassner, 2008; Mohr et al., 2010). Nevertheless, RNAi
screens are challenging (Echeverri et al., 2006; Echeverri and
Perrimon, 2006; Kaelin, 2012) and have led to reports whose
findings are not reproducible or robust enough to pursue thera-
peutically (Bhinder and Djaballah, 2013; Prinz et al., 2011).
Indeed, overlap between small interfering (si)RNA screening
results is surprising low, often less than 10% (Neumann et al.,
2010).
Each RNAi trigger has varying potency and efficacy against
its intended target and may have unwanted effects against
numerous other genes.Minimally, transfection conditions should
be determined based on efficient knockdown of known pathway
genes by a panel of siRNA triggers, resulting in a phenotypic
effect and lack of phenotypic effect with a panel of non-targeting
siRNAs. Different conditions may be optimal for different pheno-
types even within the same basic pathway. Unfortunately,
increasing the dose of siRNA often increases knockdown of
the genes of interest but reduces specificity. Ideally, the siRNA
dose should be optimized based on a phenotypic endpoint,
preferably the endpoint to be screened. In a high-contentimage-based screen involving multiple endpoints, a compro-
mise in the siRNA dose may be needed to optimize sensitivity
and specificity in asmany individual endpoints as possible. Alter-
natively, one or two primary endpoints might need to be selected
for optimizing the assay conditions.
The most common format for siRNA screens in adherent
cells remains plating cells in microtiter wells of plastic or glass
high-density tissue culture plates. Efforts are underway to iden-
tify biomaterials that more closely simulate the in vivo niche
in which the cell is found, direct the fate of stem cells, or even
pattern tissue in 2D or 3D (Lutolf et al., 2009). To facilitate cell-
based RNAi screens (Conrad et al., 2004; Neumann et al.,
2006), high-density cellular microarrays have been developed.
Arrays are created that contain dried spots with the nucleic acids
to be introduced into the cell (e.g., individual members of an
RNAi library) along with the transfection reagent to mediate their
entry. Cells are plated on top of the microarray, and transfection
occurs from below. Since the transfection reagent necessary
for a genome-wide siRNA screen can cost as much as the siRNA
library, a smaller spot size can be a considerable cost savings.
siRNA screens can also be improved through the use of aliquots
of frozen cells that are thawed and plated on top of the spotted
siRNA/transfection reagent (Swearingen et al., 2010). This re-
moves variability introduced during tissue culture and improves
workflow on screening days. Both of these approaches may
work better with cell lines than with primary cells, so successful
application may depend on the cell type.
The CRISPR-Cas9 system now allows either gene knockout or
knockdown/overexpression in cells and organisms (Gilbert et al.,
2013; Zhang et al., 2014), depending on whether a nuclease,
transcriptional repressor or activator is recruited to a particular
genetic locus. These tools are already being applied to large-
scale genetic screens (Shalem et al., 2014; Wang et al., 2014),
and some of the early results suggest that these approaches
may have a lower rate of off-target effects than conventional
siRNA. This may prove to be the method of choice in the future.
However, most of the available libraries are pooled and would
need to be arrayed for use in adherent cells, such as neurons.
In addition, gene knockout and knockdown/overexpression
screening strategies will likely offer complementary information
because knockout of essential genes may be toxic and knock-
down of other genes may be inadequate to produce phenotypic
changes. With time, the strengths and limitations of these
systems will be better understood, and that knowledge can be
incorporated into the design of libraries as well as statistical
methods for data analysis and interpretation.
With small-molecule (SM) screens, the focus is typically on an
individual target, and the assay readout is as proximal to the
target as possible. Assaying calcium flux in cells for inhibitors
of a calcium channel or substrate phosphorylation for inhibitors
of kinase function would be examples. With siRNA screening,
the focus is usually on a phenotype or pathway rather than a
single target. Most compounds in a SM library are inert in any
given assay. In contrast, because all siRNA will have some effect
on the cells (largely because of the off-target effects already
discussed), the distribution of responses is often much broader
in a siRNA screen than a SM screen (see also Birmingham
et al., 2009).Neuron 86, April 8, 2015 ª2015 Elsevier Inc. 163
Neuron
ReviewThe screens are the easiest and least time-consuming aspect
of target discovery and validation, often taking just 4–8 weeks.
However, assay development may take 6 months, and confir-
mations and validation of hits may take a full year. A plan for
prosecution of hits after a screen is critical. It should include
a flowchart with specific assays and explicit performance
criteria to eliminate genes unfit for further study and to ensure
commitment to those that are. These criteria may include addi-
tional in vitro cell systems measuring the same phenotype,
in vitro systems designed to monitor related pathways to avoid,
in vivo models of disease, gene expression from normal and
diseased human tissues of interest, toxicity liability assess-
ment, and an assessment of the druggability to name a few.
Druggability is an assessment of the likelihood of successfully
modulating the function of the protein encoded by the gene
with a SM. In general, druggable proteins contain structural
pockets that can function as receptors for SM ligands, and
are typified by classes of proteins, including G protein-coupled
receptors, nuclear hormone receptors, and enzymes, such as
proteases and kinases.
Acquiring Images
Most instruments for acquiring images in high-throughput/
high-content screening (HT/HCS) are microscope based and
designed to capture epifluorescence (Glory and Murphy,
2007). Newer electron multiplying charged coupled device
(EM-CCD) and CMOS cameras complement available CCD
technology and expand the options for sensitivity, chip size,
throughput, and cost. Newer indirect methods of automated
focusing are faster, reduce the overall amount of illumination
that the cells receive, thereby reducing phototoxicity, and
can yield more robust results than image-based approaches.
Labeling technologies have expanded significantly. Quantum
dots (Osakada and Cui, 2011; Zhang et al., 2011) are bright
fluorophores with narrow excitation and emission spectra, ideal
for multiplexing. New cell-permeable SM dyes expand the
dynamic physiology that can be measured (Vendrell et al.,
2010). Technologies, such as RNA and DNA aptamers, are being
developed as fluorescent biosensors with the potential to be
tailored to detect nearly any macromolecule (Paige et al., 2012;
Tainaka et al., 2010). Genetically encoded fluorescent proteins
remain a mainstay because they are non-invasive, can be tar-
geted to subcompartments or expressed selectively in subtypes
of cells, and can be engineered to report an array of complex
biological phenomena, such as Ca2+ binding, protein-protein
interactions, and transition metals in cells (Palmer et al., 2011;
Shekhawat and Ghosh, 2011; Vinkenborg et al., 2010). The num-
ber and properties of fluorescent proteins continue to increase.
Those that are photoconvertible are especially exciting because
they offer the potential of developing whole new types of inno-
vative assays, including the measurement of flux of specific pro-
teins and pathways at a single-cell level (Barmada et al., 2014;
Chudakov et al., 2007, 2010; Hamer et al., 2010; Tsvetkov
et al., 2013b). Light-induced stimulations can be incorporated
into screens (Levskaya et al., 2009). For applications where the
26-kD size of most fluorescent proteins is problematic, poly-
peptide labeling strategies are available (Choulier and Enander,
2010; Morris, 2010).164 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.HT cell-based screens have been performed most commonly
on fixed cells. Typically, a period of time is allowed to elapse
after a genetic or SM perturbation, the cells are fixed and immu-
nostained. An automated microscope is instructed to collect
images of the fixed cells at the appropriate wavelength(s), and
the images are typically analyzed with simple computer pro-
gramswritten in scripting language. Themethods for doing these
screens are well developed, and data can be acquired at a very
high rate. However, there are limitations. In the case of RNAi
screens, the appearance of phenotypes depends on sufficient
suppression of a gene or protein at the time the assay is per-
formed. If the images are acquired too early, the phenotype
may not be evident, resulting in a false negative. If the images
are acquired too late, the complexity of the phenotype can in-
crease due to secondary effects of the knockdown of the target.
Analogous issues arise with SM screening. To help overcome
this issue, live-cell screens are increasingly popular (Neumann
et al., 2006, 2010). Besides capturing information that might be
missed altogether with snapshot approaches, live-cell imaging
data make it possible to measure critical kinetic features of bio-
logical processes, including rapid responses to stimuli.
A major limitation of essentially all commercially available
HT/HCS systems is that they are not well equipped to handle
cellular heterogeneity. Most are designed to capture snapshots
of cell populations and compute aggregate measures from the
population. The approach is understandable, given the heavy
past reliance on immortalized cell lines, which are assumed to
be homogeneous, and historical limitations on the throughput.
Under these conditions, cell-to-cell and well-to-well variability
are assumed to represent technical rather than biological varia-
tion. But as the field increasingly moves to more physiologically
relevant systems, such as primary culture or differentiated iPSCs
(see above), aggregate population-based measures become
more problematic. These cultures are very heterogeneous, vary-
ing in maturity, subtype, and even whether they are post-mitotic.
Averaging measures from heterogeneous cell populations pro-
duces a meaningless result, and the inherent variability means
the sensitivity of the assay is low.
Recently, a form of automated imaging called robotic micro-
scopy (RM) was invented to overcome these problems (Arrasate
and Finkbeiner, 2005). It was originally designed as a hypothe-
sis-testing tool to resolve pathogenic mechanisms, incidental
changes, and coping responses (Arrasate et al., 2004) (Figure 2).
But its resolving power, particularly with heterogeneous cell sys-
tems, led to its application to HT/HCS (Daub et al., 2009; Sharma
et al., 2012) (Figure 3). Its fundamental capability is to acquire
single-cell data longitudinally, indefinitely, and in an HT manner,
allowing the investigator to acquire multivariate data from each
cell during its lifetime and then relate that information to that
cell’s fate.
The technology has evolved over successive generations. The
first generation instrument had the core capability to register
the position of a microtiter plate, which is essential to repeatedly
find the same individual cells (Arrasate and Finkbeiner, 2005).
Image acquisition was automated, but delivering plates to the
microscope was manual, and the automated focusing was
image-based, making its performance slow and its accuracy
variable. The second generation RM incorporated newer indirect
Figure 2. The Power of High-Throughput
Longitudinal Single-Cell Analysis
Conventionally, cell-based screening has com-
pared images of two unrelated cell populations
(top row). Typically, these populations differ due
to the passage of time or to a genetic or pharma-
cological manipulation of the cells. Assays often
involve a measure of cell number (each circle)
and a specific biological change/response (shown
here as a conversion from a black circle to a red
one). With this approach, it is impossible to
determine the precise relationship between the
observed biological change/response and cell
number, and variations in the number of cells
present or that exhibit a change or response under
nominally identical conditions necessarily must be
treated as technical variation, which reduces the
overall sensitivity of the system. Longitudinal
single-cell analysis overcomes these limitations
because each cell is followed over time, effectively
allowing it to serve as its own control (bottom
row). Whether a biological change or response is
associated with a change in cell number can be
measured precisely. Indeed, for assays in which
the change or response is graded, cell-to-cell
variation can be harnessed to uncover exquisitely resolved dose-response relationships. The biological significance of transient or rare changes or responses,
which might be highly significant, but dismissed with conventional approaches because of their nature, can be elucidated because they can be captured and
quantitatively linked to some future fate. For these reasons, the single-cell analysis is 100–1,000-fold more sensitive than conventional approaches for measuring
effects of perturbations on neuronal survival (Arrasate and Finkbeiner, 2005; Sharma et al., 2012), is well suited to resolve complex pathogenic and coping
responses, and is well suited to enable high-throughput screening of rare, precious, or heterogeneous cell populations (e.g., disease models based on patient-
derived differentiated human iPSCs).
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worked on microtiter plates of any well density (Sharma et al.,
2012). Importantly, software programs were developed to auto-
matically organize the images that were collected, stitch them
together into montages, organize the montages temporally into
single files, and find and track individual cells from the same
microscope field over time. The third-generation system was
designed to perform fully automated image acquisition 24/7
without human intervention (Movie S1). Plates are stored in an
automated incubator that contains a robot that delivers the plate
to a nest at specific time points prescribed by the software that
controls the system. A robotic arm transfers the plate from the
nest to the microscope stage, and the automated image acqui-
sition program begins once the plate is in place. A dedicated
robotic microscope can capture 72,000 images per day, but
usually, investigators capture 9–16 images per well, placing the
upper limit of 4,500–8,000 wells per day for assays that require
a single image. Because many of the analytical tools for quanti-
fying effects from single-cell analysis are similar to those used for
preclinical or clinical trials, the approach to power analysis is
similar. Depending on the effect size the investigator wants to
detect, the variability of the assay and the number of cells per
microscope field, it is possible to calculate the necessary wells
and even number of microscope fields the investigator should
collect per perturbagen. Most assays are HC and involve
capturing images of 2–4 reporter genes at different
fluorescence wavelengths. Once an imaging run is finished, the
robotic arm transfers the plate back to the incubator. A new
fourth-generation system has just come on line and achieves
higher throughput and content by incorporating fast dual
CMOS cameras with a beam splitter and an Andor C1 spinning
disc confocal to achieve better spatial resolution and to make4D movies. In addition, we are integrating new single-cell tran-
scriptomic technology to investigate the cell-specific pheno-
types we observe in greater depth (Actis et al., 2014).
As a practical matter, multiple screens for different collabora-
tors are run simultaneously, and so each of these screens is
assigned a fraction of the overall throughput. It is important to
point out that, although the throughput of these systems is sig-
nificant, throughput is not their distinguishing feature. Higher
throughput systems exist. The distinguishing feature is the longi-
tudinal single-cell nature of the measurements, which confers a
substantial increase in sensitivity and expands the types of
biology assays that can be performed. If these features are not
critical, then conventional population-based HTS methods will
likely be cheaper and faster. Although the technology was
invented in the Finkbeiner Laboratory, the essential capability
to perform longitudinal single-cell analysis has since been
established in other academic laboratories (Nagai et al., 2007;
Wen et al., 2014a).
Image Analysis and Visualization
Analysis of cell-based imaging results from SM or genetic
screens involves two steps: (1) extraction of features from the
raw images, and (2) analysis of those measurements to identify
any significant patterns. Currently, image analysis begins by
measuring a discrete and narrowly defined phenotype from an
image (e.g., neurite length, cell survival, and mitochondrial
morphology). Analysis programs are written to detect some
pattern and/or intensity of the pixels in the image that corre-
spond to a feature of interest and measure it as accurately as
possible.
Unfortunately, the number and complexity of features that
can be extracted are severely limited. A trained researcher canNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 165
Figure 3. Analysis of Longitudinal Single-Cell Data from Screens in Primary Neurons
(A) Shows a typical montage of microscope fields at the first-time scan after image segmentation. Unique cell-track numbers are shown in red next to each cell.
There are two regions within this montage that have been zoomed in to show cell lifetime detection from the entire time-lapse imaging data set to illustrate the
ability to do longitudinal single-cell analysis.
(B) A typical delimited text file showing the arrangement of data output and feature extraction by the analysis program.
(C) A representative heatmap of a control plate in which a knownmodifier, the trophic factor brain-derived neurotrophic factor (blue outlinedwells), was spotted at
different doses throughout the plate in the midst of positive control wells (green outlined wells) and analyzed in a blinded fashion. White shaded wells indicate
longer survival and dark red shaded wells indicate reduced survival. The numbers represent the cumulative death in each well at the end of the experiment. This
survival assay had a positive predictive value of 91% and a negative predictive value of 97%, underscoring the highly sensitive and specific nature of RM.
(D) A survival curve from a modifier well showing decreased hazard (increased survival), compared to the negative control wells. Adapted with permission from
Sharma et al. (2012).
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However, manual annotation is not an option, given the large
volumes of data produced. This situation is changing with
more computational power. Along with better performance
of standard pixel level feature identification, more powerful
machine perception software and massive machine resources
can now be applied.
Automating feature extraction is a great step forward, but
also makes analyzing the data much harder just by the simple166 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.mass of data that can be rapidly accumulated. To find mean-
ingful correlations and patterns in highly dimensional feature
spaces requires complex algorithms and a lot of computational
power. Fast and effective visualization tools can help, but as
the number of dimensions grows, visualization is not enough.
More use of better statistical analysis algorithms that auto-
matically search for interesting patterns in the data are crucial.
Also, increasingly powerful ML techniques can generate
models and use them to both make predictions and direct
Neuron
Reviewexperimentation to test these predictions, thereby improving
the models iteratively.
Analysis of longitudinal single-cell data utilizes a suite of statis-
tical tools, called survival analysis, which is used commonly for
clinical trials and in time-to-failure studies in engineering (Dekker
et al., 2008). Survival analysis and the closely related Cox
proportional hazards analysis (Wolfe and Strawderman, 1996)
allow predictive statistical models of fate to be built from the vari-
ables that are tracked during the experiment. These approaches
can be adapted further into Bayesian hierarchical analysis
models, which avoid some of the assumptions of frequentist
approaches and do a better job handling measurement errors
(Miller et al., 2010, 2011). The approach can answer questions
that elude conventional approaches (i.e., What is the biological
significance for fate of a change I see during the cell’s lifetime?).
For example, when applied to the study of mechanisms of
neurodegenerative disease, it can distinguish thorny and highly
interrelated pathogenic processes from coping ones and assign
an importance to them based on the quantitative measure of
the fate those processes predict.
Single-cell analysis overcomes many of the inherent problems
of the population-based approaches described above. Because
each cell is followed over time, phenotypes that emerge at
any time over the course of the experiment are captured. Even
stochastic and informative rare events can be captured at a
sufficient level to draw clear conclusions (Barmada et al.,
2010). The cell-to-cell variability that reduces the sensitivity of
population-based approaches can be harnessed with RM to
add additional power to the analysis. For example, the dose
of RNAi or other perturbant each cell receives varies from cell
to cell, but it can be estimated from the fluorescence of a marker
that is co-introduced (Arrasate and Finkbeiner, 2005). Then, after
the experiment is done, and the fate of the cell is measured, and
the relationship between the dose a cell received and the fate
it experienced is quantified.
The abilities of the system to connect the extent of a perturba-
tion to the response on a single-cell level over thousands of cells,
to effectively allow each cell to serve as its own control, and to
avoid confounds of cell death and cell division make it about
100–1,000 times more sensitive for measuring the effects of
perturbagens on neuronal survival than commercially available
systems that depend on snapshots (Arrasate and Finkbeiner,
2005; Sharma et al., 2012) (Figure 3). The approach is an
especially goodmatch for heterogeneous primary cell and differ-
entiated iPSC systems, since markers of cell type can be
introduced so that different cell types can be identified and their
biology can be monitored separately. This likely made it possible
to measure disease-relevant phenotypes in iPSC models of HD,
ALS, and Parkinson’s disease without the need for exogenous
stressors, which has been difficult to do with other methods
(Bilican et al., 2012; HD iPSC Consortium, 2012; Serio et al.,
2013; Skibinski et al., 2014). With this high level of sensitivity,
conclusions can be drawn about the effects of pharmacological
or genetic modifiers with data from as few as eight cells per well,
which has made screening with primary cells and iPSCs—even
genome-wide siRNA screens and large SM screens—feasible.
The imperative for single-cell analysis is increasingly being
recognized (Mullassery et al., 2008; Wu et al., 2011), and it hasbeen applied in vivo to do imaging in Caenorhabditis elegans
(Murray et al., 2006) and in cell lines to understand the biological
significance of variability in signaling (Bendall et al., 2011).
Cell-based imaging screens generate staggeringly large and
complex data sets. However, the brain is limited in the number
of data dimensions and tradeoffs that can be considered at the
same time. Without tools to graphically visualize the results of
the analysis and present them quickly, it is difficult to grasp
important patterns or trends in the data. Access to both raw
data and useful visualizations is critical. Visualization is most
helpful in an iterative process where looking at one visualization
raises questions that are illuminated by another and so on. The
difference between taking a few seconds to present visualization
results and a few minutes is often the difference between a
system being used frequently or not used at all. While there will
never be enough computational power to precompute visualiza-
tions of all possible interesting aspects of complex data sets,
educated guesses can determine which visualizations are most
likely to be useful. Those initial guesses can be improved by
automatically monitoring the usage of the visualization system.
The ready availability of greatly increased computational
power should enable a much broader use of statistical investiga-
tion. It should become common practice to run basic statistical
algorithms to investigate correlations between most pairs of
variables, and even some selected tuples, in any data set. This
can be done in the background and presented to researchers
in a way that makes it easy to check for surprises or anomalies.
For repeated sets of experiments, the analysis of the deltas
in such correlations between experiments can also yield useful
insights.With attribution algorithms, it is even possible to analyze
the attribution of changes to important observations and auto-
matically point out the responsible variables/features (Sun and
Sundararajan, 2011). Other tools, such as parallel R and RFAce
(https://code.google.com/p/rf-ace/), allow statistical algorithms
to be run on large computer clusters.
For statistical algorithms, just like with visualization, compu-
tational power cannot grow as quickly as the combinatorics of
complex data sets. The possible sets of variables and the
possible analyses to be run will always outstrip new increases
in computational power. However, with increased computational
power, every experiment should have an exploratory computa-
tional budget. The question should shift from whether to apply
statistical and data mining techniques at all to which variables
and techniques to consider, given a specific computational
budget. We should move from a world in which more data are
considered a hindrance to one in which the ability to throw
more related data into the automated analyses we set up for
any experiment is seen as a benefit for the potential insights it
might engender.
In parallel, better statistical algorithms need to be created.
A little-known fact in HTS is that the statistical tests of signifi-
cance utilize analysis methods that are catastrophically ill-suited
to the task. Generally, these tools were designed for data sets
in which few hypotheses were tested repeatedly. In HTS, many
hypotheses are tested once each. One promising approach
is to adapt some of the solutions that have been developed
for analysis of microarrays where statisticians have already
grappled with similar challenges.Neuron 86, April 8, 2015 ª2015 Elsevier Inc. 167
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ML is a technique for building predictive computational models
of a phenomenon that are iteratively improved with new facts
or evidence. Both supervised and unsupervised learning ap-
proaches are promising (Conrad et al., 2004; Glory and Murphy,
2007; Jones et al., 2009; Neumann et al., 2010; Shamir et al.,
2010). ML is a rich and rapidly advancing field of computer
science, and there aremanyML techniqueswith varying degrees
of complexity and computational requirements. At a very high
level, an ML system represents entities as sets of features.
A feature is something measurable about the entity. All of the
features of an entity can be combined into a fingerprint that
describes that entity. TheML system builds an internal represen-
tation of how various combinations of feature values for an
entity (its fingerprint) can predict something about that entity.
As the system makes predictions, they are either confirmed
or rejected. This feeds back into the ML system and causes it
to update its representation. Over many iterations, the system
learns to do better and better prediction. Although ML is not a
new field, in most situations, the amount of data and computa-
tion needed to make it applicable to non-trivial problems are
only now becoming generally available.
Besides the insights that these approaches provide for image
analysis, they offer an attractive framework for incorporating
additional disparate data. For example, it is possible to integrate
whole-genome sequencing data and information on the patient’s
diagnosis, clinical course, and response to medicines with
patient-derived iPSC screens. ML has the potential to uncover
cellular phenotypes from the imaging data that elude humans
and to integrate the additional genetic and clinical data with
the phenotypic data in ways that could ultimately help us create
a target and therapy discovery platform that is more predictive
for clinical trials and lead the way for a personalized medicine
approach to diagnosis and to treatment.
ML algorithms often give insight into complex systems when
they give predictions that are surprising but correct. The investi-
gation of why non-intuitive predictions are correct often leads to
new testable hypotheses. But beyond insight, these systems can
be practically applied to solve problems with feedback loops.
For example, if an ML system were built to recognize hand-
writing, and it learned that some complex combination of
features predicted that the letter being written was Q, this fact
could still be effectively used even if a human couldn’t make
sense of ‘‘why’’ those features predicted Q. ML systems could
potentially also be applied to repetitive tasks, such as growing
specific cells or tissues from iPSCs. As long as the ML system
effectively and continuously determined what combinations of
features led to better yield, it would provide benefit even if the
exact reason for its success wasn’t immediately understood.
Machine perception is another technology that relies on ML
techniques, and it is coming of age as increased computational
abilities make it possible to execute the algorithms required.
More and more experiments produce results that are images
or video that require a non-scaleable application of human
effort to interpret. Like all data, each image or video is still repre-
sented as a set of bits. With the right feature extraction, it can be
fingerprinted, and ML can be applied. If the right representation
can be built to predict things about the images based on these168 Neuron 86, April 8, 2015 ª2015 Elsevier Inc.features, a level of understanding of the image or video is
achieved. More so than in simpler data types, which features
to extract becomes critically important. Some recent success
has been attained with patterning feature extraction on how
the human visual cortex processes input (Le et al., 2012).
As we move beyond visualization and apply statistical and ML
techniques to large data sets, we can gain new insights into
our data and even create practical feedback control loops.
Another under-appreciated aspect of these techniques is
that they are free of human bias. This has both an upside and
a downside. The upside is that truly novel insight can be gained
because these techniques can find patterns in the data that are
far outside the scope of where a researcher would normally look.
The downside is that these patterns are often not particularly
germane to the problem being investigated and often wind up
being artifacts of experimental setup or algorithm design.
Balancing this upside and downside is an important aspect of
working with ML techniques.
The Future
Rapid advances are expected in the near future in all aspects of
cell-based screening, including cell-based disease modeling,
imaging, and analysis. The number of nervous system cell types
that are possible to make and the efficiency with which they can
be produced inexorably increases. Many existing differentiation
protocols have aimed to recapitulate development through the
addition of exogenous factors at key time points, which can be
slow and inefficient. Increasingly, genetic and SM perturbations
are being used, which can create ‘‘short cuts’’ that reduce the
time and cost and improve the efficiency of differentiation (Victor
et al., 2014; Zhu et al., 2014). Interestingly, MLmay havemuch to
offer biologists seeking to solve the unwieldy combinatorial
problems involvedwith refining differentiation protocols. Another
focus in the differentiation field is the development of protocols
that make subtypes of nervous system cells (Maroof et al.,
2013). There is still a widespread concern that even after differ-
entiation, the cell types that are produced are immature and
may be unable to recapitulate critical dimensions of disease-
related biology that require a certain level of maturity or even
aging. Investigators are experimenting with ways to age iPSC
cultures naturally or to accelerate the aging process genetically
(Miller et al., 2013).
The field has understandably been focused on the develop-
ment of differentiation methods that produce specific defined
cell types. But the nervous system is a complex tissue whose
normal function is an emergent property of many cell-cell inter-
actions. For example, the physiology of neurons is very different
if they are grown alone or if they are grown with astrocytes, and
many critical structures, such as the synapse, the myelinated
axon, and the neuromuscular junction, require the presence of
multiple cell types (Pfrieger and Barres, 1997; Ullian et al.,
2001). Clearly, a critical future goal of the field will be to reconsti-
tute nervous system structures that require multiple different
cell types. This represents a major challenge to the iPSC field
because the protocols to make neurons, astrocytes, microglia-
like cells, skeletal muscle, and oligodendrocytes are very
different. In some cases, it has been possible to differentiate
different types of mature cells from the same iPSC line and
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Figure 4. Future Applications of High-
Throughput Cell-Based Screening
The increasing ability to collect complex cell-
based and clinical data and to analyze these data
with ML approaches is opening up new possibil-
ities for high-throughput cell-based screening.
The figure illustrates an initiative being pursued by
the authors (S.F. and M.F.) to develop a preclinical
pipeline that is more predictive of clinical results.
An element of the overall approach, supported by
the NIH Common Fund and National Institute of
Neurological Disorders and Stroke, involves the
creation of an array of hundreds of biosensors
suitable for longitudinal live single-cell imaging
and capable of generating a deep phenotypic
understanding of a variety of cell structures and
functions in brain cells from patient-derived iPSCs. The array of biosensors is referred to as the ‘‘Physical Exam of the Cell’’ and is designed to broadly survey cell
physiology, performing a role at a cellular level similar to the role that the physical exam of patients plays in medicine. These large and complex data sets will then
be related to similarly deep and complex clinical data sets collected from the patients fromwhom the iPSCs were generated. Then, with unsupervisedML, the two
data sets can be examined with the goal of finding features that can be measured from iPSCs that predict one or more clinical features, such as disease pro-
gression, of the patients from whom the cells came. New or additional clinical features may be predicted as the iPSCmodels of disease increase in physiological
relevance with improved differentiation protocols or by combining different cell types that lead to emergent properties. A preclinical pipeline that predicts clinical
findings could be invaluable for lowering the risk of developing neurotherapeutics by improving the sensitivity of clinical trials through patient stratification and for
identifying therapeutic targets and therapies that have a better chance of working when tested in patients.
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interest (Serio et al., 2013). A related goal is to model neural
circuits with human neurons. Technology to engineer neural
circuits in vitro has been developed and needs to be applied to
the iPSC field (Garcia et al., 2012; Li et al., 2014; Shein et al.,
2009; Shein-Idelson et al., 2011). Notably, as model systems
become more complex, the ability to distinguish different cell
types and track their biology independently will become even
more important for extracting useful data from these heteroge-
neous systems.
Regardless of the particular screening method or disease, the
general concepts governing cell-based screening discussed in
the review will likely remain valid. That said, there are likely to
be some exciting new directions in cell-based screening. The
availability of a fully human iPSC-based platform to evaluate
perturbagens by HTS opens up several interesting new possibil-
ities. Human genetics has played a critical role in identifying
genes and pathways that are responsible for neuropsychiatric
disease. But achieving the statistical power to uncover substan-
tial numbers of interesting genetic variants remains challenging
to do because it can be difficult to find enough patients and
to afford the costs. In addition, as genetic analyses extend
more deeply into non-coding regions of the genome, it becomes
even more critical to perform functional validation studies
to establish causal relationships between genetic variants and
disease. An HT iPSC-based platform could be used to screen
putative genetic variants against disease-relevant phenotypes
to quickly narrow putative variants, some of which may not
have achieved genome-wide significance using human genetic
analysis alone, down to a set that have significant functional
effects in a fully human system. We could envision a future in
which human genetics and HT screening in human CNS models
are combined to advance or regress the candidacy of putative
disease-modifiers and simultaneously obtain critical functional
validation.
With the incorporation of more relevant primary neuron and
iPSCs into HTS and the substantial financial investment that
entails, the economics of screeningwill change. It will be increas-ingly important to extract as much phenotypic information
as possible from each screen to justify the expense, and that
will likely lead to the design of screens that incorporate multiple
biosensors to track independent endpoints. In this context,
one of the biggest remaining limitations in image acquisition is
the bandwidth available to resolve different fluorophores. The
broad excitation and emission spectra of fluorescent proteins
make it difficult to use more than three or four simultaneously
with conventional filter-based methods to resolve signals.
Several approaches to increase the content of screens are
under investigation. For example, pixel-by-pixel spectra can be
generated, and complex overlapping emissions can be linearly
unmixed to distinguish more fluorophores than is possible with
conventional filter-based techniques. However, these methods
are still too slow for HTS and will require modification. In screens
with live-cell imaging, additional terminal assays can be per-
formed after fixing the cells, thus adding content. These can
include the selected application of approaches, such as super-
resolution microscopy (Bates et al., 2007, 2008; Ding et al.,
2009; Grecco and Verveer, 2011) that might be too slow or
resource intensive to apply to all the samples in the screen.
This can be done through an image-based servo mechanism
to direct the instrument to collect the additional data from spe-
cific fields of interest identified through automated image anal-
ysis.
Predictably, CPU, storage, and bandwidth will all become
cheaper, and more computational resources will become avail-
able, giving researchers much more powerful techniques for
analysis at their disposal. Before any of the techniques above
can be used, the nuts and bolts of infrastructure problems of
storing, manipulating, moving, and safeguarding data must be
solved. Cloud computing solutions will offer simpler alternatives
to building everything in the lab, but will potentially complicate
other factors like bandwidth and security.
The availability of very large-scale computational power pro-
vided by large networked clusters will change the way science
is done.We are already seeing the benefits of running existing al-
gorithms in parallel on much larger data sets. Better and fasterNeuron 86, April 8, 2015 ª2015 Elsevier Inc. 169
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phenomena. The real change will come from applying algorithms
that were previously untenable due to computational limitations.
These algorithms will, in turn, drive a different approach to
investigation.
As techniques, such as ML, machine perception, large-scale
modeling, and simulation becomemore common, theway inves-
tigators look at problems should change to take advantage of
these tools. Adoption of these changes is slow and likely reflects
that large-scale approaches are not practical without access
to large computational facilities. The problem may be partly
overcome by the availability of large-scale computing power
by the slice from third-party vendors, such asGoogle or Amazon.
Another reason for the slow adoption of some of these tech-
niques is lack of expertise. ML, simulation, machine perception,
visualization, and even the basics of managing large data are all
difficult problems that require experts to solve. There is no sim-
ple cookbook for applying these techniques to a given problem.
The limited supply of people with such experience is dwarfed by
the demand. This is a problem that is only fixable by our educa-
tion system in the long term, but can be ameliorated by collabo-
ration in the short term.
As computational resources become cheaper and more
available, researchers will have exciting new options in how
they pursue their research. Perhaps the most exciting future
directions for cell-based screening will emerge from the effective
combination of advances in cell-based modeling, imaging, and
ML. As cell-based assays become more complex and generate
deeper cellular phenotypes, can we use ML to help us prioritize
the phenotypic endpoints that will translate best and that
should be pursued? The availability of more powerful forms of
image analysis, powered by techniques such as deep learning,
may lead to a fundamental shift in phenotypic screening, away
from simplistic measures of narrow endpoints to more global
definitions of cell health. With the ability to produce deep cellular
phenotypes in patient-derived iPSCs, will it be possible to use
ML to predict features of the clinical course of patients from
whom they came (Figure 4)? If so, it could transform approaches
to patient stratification, clinical trial design, and improve the
reliability of our translational pipeline. We are now entering a
period of time where the availability of such computational
resources will grow exponentially and so will the development
of new algorithms and techniques that take advantage of these
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